Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma
Ramucirumab is a fully humanized monoclonal antibody targeting the extracellular domain of the VEGF receptor 2. It prevents ligand binding to VEGF receptor 2 and receptor-mediated pathway activation in endothelial cells. After promising Phase I trial results in a variety of tumor types, two pivotal...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
02 Jun 2015
|
| In: |
Expert review of anticancer therapy
Year: 2015, Volume: 15, Issue: 6, Pages: 607-614 |
| ISSN: | 1744-8328 |
| DOI: | 10.1586/14737140.2015.1052412 |
| Online Access: | Volltext Volltext 
|
| Author Notes: | Ralf-Dieter Hofheinz and Sylvie Lorenzen |
| Summary: | Ramucirumab is a fully humanized monoclonal antibody targeting the extracellular domain of the VEGF receptor 2. It prevents ligand binding to VEGF receptor 2 and receptor-mediated pathway activation in endothelial cells. After promising Phase I trial results in a variety of tumor types, two pivotal placebo-controlled Phase III trials conducted in patients with pretreated metastatic esophagogastric adenocarcinoma demonstrated significant clinical activity regarding the prolongation of overall survival both as monotherapy (REGARD study) and in combination with paclitaxel (RAINBOW study). Currently, ramucirumab is being investigated in the first-line treatment of esophagogastric adenocarcinoma in combination with capecitabine and cisplatin in a Phase III trial (RAINFALL). |
|---|---|
| Item Description: | Gesehen am 05.01.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1744-8328 |
| DOI: | 10.1586/14737140.2015.1052412 |